

DBT's Health Tech Showcase

London Stock Exchange
5 June 2024



Opportunities for international Venture Capital funds to invest in leading UK
Health Tech start-ups

Contents

• Disclaimer	3
• About us	5
• Agenda	6
• Company details:	
• CardiTec Therapeutics	7
• Turing Bioscience	8
• CoSyne Therapeutics	9
• Sixfold Bioscience	10
• Imperagen	11
• Oxford Drug Design	12
• Valink Therapeutics	13
• PharmEnable Therapeutics	14
• BIOS	15
• Constructive Bio	16

Disclaimer

This document contains limited confidential information with respect to a selection of UK Health Tech firms (referred to individually as a “UK firm”) and is being provided to certain qualified accredited investors solely to assist such investors in determining whether they want to consider conducting their own further due diligence investigation of each such UK firm in connection with a potential transaction with that UK firm. If an investor determines it wants to consider a transaction, that prospective purchaser will need to contact the UK firm for more detailed information and an opportunity to conduct its own due diligence of that UK firm. No investment decision should be made on the basis of this document, which has been prepared by the Department for Business and Trade (DBT) for informational and discussion purposes only. This document has not been prepared by DBT in the course of carrying on a business.

DBT is not authorised or regulated by the Financial Conduct Authority and is not registered with the United States Securities and Exchange Commission.

ACCURACY OF INFORMATION

This document does not purport to be exhaustive or to contain all the information relating to each UK firm that a prospective purchaser may require before participating in a transaction. DBT does not make any representations or warranties, whether express or implied, and accepts no responsibility as to the accuracy, completeness or reasonableness of the information contained herein. Any prospective purchaser that is interested in participating in a transaction is recommended to seek and obtain independent advice from its own financial, tax and legal advisors.

NO ENDORSEMENT OR RECOMMENDATION

DBT does not recommend or endorse any of the UK firms named in this document. There is no association or legal relationship between DBT and any of the UK firms named in this document by virtue of the references to such UK firms in this document. No representation or warranty, whether express or implied, is given by DBT as to the character or professional ability of any UK firm named in this document, or any goods or services a UK firm named in this document may offer. You are responsible for conducting your own research and due diligence before entering into any contract with, or making any investment in, any UK firm named in this document and you should not place any reliance on the information in this document.

NO SOLICITATION OR OFFER TO SELL

This document is not, and should not be construed as, an offer to sell or a solicitation of an offer to buy any securities of or to make any investments in, any company in any jurisdiction. Neither the United States Securities and Exchange Commission nor any State Securities Commission has approved or disapproved or will approve or disapprove of any securities or passed upon the accuracy or adequacy of any information or the merits of any transaction. Any representation to the contrary is a criminal offense under US law. No sales will be made, no commitments to invest in any company will be accepted, and no money is being solicited or will be accepted in connection with this document. Any indication of interest from prospective investors in response to this presentation involves no obligation or commitment of any kind. The information contained herein is provided on a confidential basis for informational and discussion purposes only, to a limited number of investors that are qualified accredited by the regulatory body appropriate for their region or ‘sophisticated investors’ wherein DBT considers that a person has sufficient knowledge and experience in financial and business matters to evaluate the merits and risks of the prospective investment.

INVESTMENT RISKS

This document does not purport to summarise all of the conditions, risks and other attributes of any investment product or of any UK firm. Investing entails a high degree of risk and is suitable only for sophisticated investors and requires the financial ability and willingness to accept the high risks and lack of liquidity inherent in an investment. The value of investments can fall as well as rise and you might not get back the amount originally invested at any point in time. Investors in any UK firm must be prepared to bear such risks for an extended period of time. A UK firm's past investment performance is not a guarantee or predictor of future investment performance.

This document may contain certain estimates, projections and forward-looking statements of a UK firm based on various estimates and assumptions that are subject to substantial risks and uncertainties beyond the control of DBT or that UK firm. There can be no assurances that projected results, if any, will be realized or that actual results will not differ materially from those projected.

Nothing in this document constitutes investment, legal, financial, accounting or tax advice. All information contained in this document is of a general nature and does not address the objectives, financial situation or needs of any particular entity. You must obtain independent specialist advice before entering into any contract with, or making any investment in, any UK firm named in this document.

CONFIDENTIALITY

This document is strictly confidential and solely for the use of the persons to whom it is provided. This document may not be disclosed, reproduced or further distributed, in whole or in part, for any purpose without DBT's prior written consent, except that any person to whom this document is provided, may share this document with other persons within their firm who are qualified accredited investors. The terms of this disclaimer shall apply to any such other persons to whom this document is provided.

LIMIT ON LIABILITY

To the fullest extent permitted by law, no liability is accepted by DBT for any loss or damage, whether consequential or otherwise, which may arise out of or in connection with the use of or reliance on any information in this document. Any contract entered into, or investment made based on any information in this document is entirely at the risk of the person entering into the contract or making the investment.

THE UK NATIONAL SECURITY AND INVESTMENT (NSI) ACT

The UK National Security and Investment (NSI) Act took effect on 4 January 2022 and will require certain types of M&A transactions, including equity investments, in 17 sectors to be notified to a dedicated government unit, the ISU, for review. DBT Venture Capital Unit will continue to match investors with relevant UK investment opportunities and can provide guidance on engaging ISU. We're unable to provide further advice or legally binding guidance on notifications, but to be aware: mandatory notification occurs when new or existing ownership stakes pass thresholds of 25%, 50% and 75%. However, the ISU may itself review transactions outside of these parameters. Detailed information about the NSI Act can be found at [gov.uk](https://www.gov.uk).



Department for
Business & Trade

About us

Department for Business and Trade:

The UK's Department for Business and Trade (DBT) secures global prosperity by promoting international investment, and championing free trade. DBT's Venture Capital Unit (VCU) matches qualified investors with opportunities across strategically important sectors in the UK. Our efforts support companies to scale up, launch next-generation products and services, and expand their international presence, creating highly skilled jobs and growth in the UK.

Venture Capital Unit

Investment Directorate
Old Admiralty Building, Westminster
London
SW1A 2BL
Telephone: +44 (0) 207 215 5000
Email: VentureCapitalUnit@trade.gov.uk
Website: [Venture Capital Unit](#)

Department for Business and Trade

Venture Capital Unit - Health Tech Showcase

London Stock Exchange 10 Paternoster Sq., London EC4M 7LS
 5 June 2023, 12:00-17:00

Timing	Programme
12:00 – 13:00	Arrivals, lunch and initial networking
13:00 – 13:15	Welcome from DBT’s Venture Capital Unit (VCU) and London Stock Exchange (LSEG) Paul Morris, Senior VC Advisor (DBT) and Tim Davis, Regional Head, Primary Markets (LSEG)
13:15 – 13:35	Keynote address Steve Bates OBE, CEO, UK BioIndustry Association
13:35 – 13:40	Pitch introductions Paul Morris, Senior VC Advisor (DBT)
13:40 – 14:30	First set of pitches – early stage: • CardiaTech Biosciences – Raphael Peralta, CEO • Turing Biosystems – Adam Amara, Co-Founder • CoSyne Therapeutics – Louwai Muhammed, CEO • Sixfold – Anna Rosell, Co-CEO • Imperagen – Andrew Almond, CEO
14:30 – 15:00	Coffee and networking break
15:00 – 15:55	Second set of pitches – growth stage: • Oxford Drug Design – Alan Roth, CEO • Valink – Irsyad Khairil, CTO • PharmEnable Therapeutics – Hannah Sore, CEO • BIOS – Emil Hewage, CEO • Constructive Bio – Ola Wlodek, CEO
15:55 – 16:00	Closing remarks Paul Morris, Senior VC Advisor (DBT)
16:00 – 17:00	Drinks and networking

CardiaTec Biosciences



Round

- £5,000,000
- Seed
- Open

Current Investors

- Apex Ventures
- Cambridge Enterprise
- Laidlaw Ventures
- Crista Gali Ventures
- O2h Ventures
- Francis Crick Institute

Company HQ

- Cambridge, UK

Employees

- 10 FTEs

VALUE STATEMENT

CardiaTec is a TechBio company employing computational modelling to decode the biology behind cardiovascular disease. The company leverages large multimodal human data to identify novel and differentiated therapeutics.

CardiaTec is building the largest proprietary human heart tissue multi-omics dataset. The company has strong academic links and a network of 65 US hospitals from which whole human hearts are procured, with paired electronic health records and blood samples. The company spun out of the Han Lab at the University of Cambridge and has brought together industry experts from leading organisations including Bristol Myers Squibb, Cleveland Clinic and Recursion Pharmaceuticals.

MARKET INDICATORS

Cardiovascular disease is the global leading cause of death. The cardiovascular drug discovery market is valued at over \$37bn. Nonetheless, the discovery process suffers from costly, low-throughput clinical programmes with lower success rates compared to other indications. This has largely been due to a limited understanding of the complex and chronic nature of cardiovascular disease biology. The AI Drug Discovery (AIDD) market is valued at £1.5bn with a +30% CAGR. With the recent democratisation of sequencing technologies, CardiaTec is now leveraging large multimodal data to generate high-dimensional maps of cardiovascular disease biology. Through AI-enabled analysis, we can navigate a broad data space, supporting the discovery of more disease relevant and novel first-in-class therapies. CardiaTec is the first company to specialise in cardiovascular AIDD, opposed to being in oncology, which currently dominates the field.

TRACTION INDICATORS

Multimodal AI platform spun out of the world leading computational lab at the University of Cambridge, Milner Therapeutics Institute (MTI). Large hospital network for proprietary sample acquisition and data generation. X2 company Co-founders recognised as Forbes 30Under30, 2024.

STAGE INDICATORS

Company founded in Sep 2021. Raised £1.5m to date. Raising £5m to take model predictions into wet lab validation, expand our pipeline into our second indication and sign our first partnerships with a large pharmaceutical company.

STRENGTH OF TEAM

- **Namshik Han, CTO & Co-founder:** Prof & Head of AI, MTI, Uni of Cambridge.
- **Raphael Peralta, CEO & Co-founder:** BD at Vector Bio, MPhil Bio Enterprise, Uni of Cambridge.
- **Thelma Zablocki COO & Co-founder:** M Ventures, MPhil Bio Enterprise, Uni of Cambridge.

Turing Biosystems



VALUE STATEMENT

Turing Biosystems provides a precision medicine and drug development software platform based on multimodal explainable reasoning AI. Their platform delivers actionable insights on patient response to a drug and side effects, based on real patient biology. They build digital twins of entire tumours to provide a live and actionable understanding of the tumour microenvironment, to see how new drug candidates will impact the fight of the immune system against cancer cells. Turing's software platform is based on a proprietary high performance graph database engine optimized for the use cases of life sciences. The reasoning AI is accelerated on redesigned FPGA chips, for pharma R&D to be able to test hypothesis and iterate on drug design in the fastest way possible.

Round

- £5,500,000
- Seed
- Q2 2024

Current Investors

- Creator Fund
- January Ventures
- Another.VC

Company HQ

- London, UK

Employees

- 8

MARKET

The biotech and pharma industries are facing exploding costs for R&D and clinical trials (up to \$1bn+ for a drug to get to market), high drug failure rates (30-70% of patient do not respond in oncology). Patients often experience many adverse events (up to 75% of patients) and many drugs do not reach market. Regulators request more evidence of drug efficacy and reduced side effects. Patents for current blockbuster drugs will expire in the next few years with \$200bn/year at risk.

TRACTION INDICATORS

First R&D pilot contract with Sanofi in immuno-oncology, in negotiation for expansion into a larger partnership with several teams internally.

R&D partnership with a gene therapy biotech to find immunomodulators to reduce immune side effects to an AAV-based gene therapy in Phase III. Network of hospitals for multimodal patient data access. Enhancing partner ROI by increasing safety & efficacy in clinical translation.

STAGE INDICATORS

Turing Biosystems has raised a pre-seed round of £890k in December 2023. The company is currently raising a seed round of £5.5m.

STRENGTH OF TEAM

- Adam Amara, CEO, PhD, designed the multiomics data integration system of IARC-WHO for massive cohorts of cancer patients (500K+).
- Remy Boutonnet, CTO, PhD, built software in the semiconductor industry to design & optimize chips for customers like Apple, Intel, Microsoft and defense providers.
- Team of software engineers from quantum chemistry, astrophysics, to bioinformatics engineers from Cambridge University & WHO.

CoSyne Therapeutics



Round

- £15,000,000
- Series A
- Q3 2024

Current Investors

- LocalGlobe
- Backed VC
- Start Codon
- Amino Collective
- Meltwind

Company HQ

- London
(computational biology)
- Cambridge
(experimental biology)

Employees

- 22 FTEs and 10 advisors

VALUE STATEMENT

CoSyne is digitising biology to find new ways to treat diseases. By combining biology and computation, they are transforming the search for new drugs from a science problem into an engineering problem. The company's approach brings the speed and rapid feedback loops from the technology sector into the biology sector.

CoSyne collect brain resection samples from human patients and use state-of-the-art genetic tools to generate large amounts of data from those samples. They use this data to train AI models that can predict new ways to treat diseases. This allows them to develop drugs that can treat patients with these diseases.

MARKET INDICATORS

The market for drug prioritisation is estimated to reach \$31 billion dollars in 2028 with a CAGR of 2.9%.

TRACTION INDICATORS

CoSyne won an Innovate UK Smart Grant and is in discussion with several pharmaceutical companies interested in benefiting from their biological insights.

STAGE INDICATORS


Company raised a £6m seed round in May 2022, which was used to acquire surgical brain resection tissue from 70 patients in the US and UK. They then developed a high throughput methodology to digitise the biology of those cells, which has allowed them to identify multiple drug targets in a variety of neurological diseases. The Series A will allow CoSyne to develop several compounds and prepare the pivotal clinical trials needed to get these drugs to the right patients.

STRENGTH OF TEAM

Dr Louwai Muhammed (CEO & Co-founder): Clinical neurologist, studied neuroscience at Cambridge and clinical medicine at Oxford. Kennedy Scholar at Harvard. Winner of the MIT-\$100K Accelerate competition. Established an internationally recognised teaching platform for medical students in war-zones.

Dr Liisi Laaniste (CSO & Co-founder): PhD from Imperial College London in Computational Systems Biology. Almost a decade of research on brain tumours, cancer genetics and pathways of malignant transformation. Studied neuroscience in Karolinska Institute, medical science in Uppsala University.

Professor Michael Johnson (CMO & Co-founder): Professor of Neurology and Genomic Medicine at Imperial College London with over 15-year's experience with pharmaceutical and biotechnology companies. Over 20-years' experience as Principle Investigator and as a consultant clinical neurologist.



VALUE STATEMENT

Sixfold Bioscience aims to solve one of the most critical challenges preventing the greater utilization of RNA therapeutics: delivery.

Digitisation and advances in AI/ML are opening up vast opportunities in life sciences (e.g. AlphaFold), but the application to RNAi delivery has been limited by the inability to generate relevant *in vivo* data. Sixfold has built the infrastructure to solve this by pioneering research in generative-ML, chemical engineering, automation and multiplexed scSeq studies. To use a software analogy: this is the OS of RNA, a critical step in making individual cell populations addressable in the human body.

MARKET INDICATORS

RNA's potential is vast, but its reality is limited due to the fact that current RNAi delivery modalities can only target less than 1% of the ~500 human types cells. The GalNAc conjugate, which delivers siRNA and ASOs to one cell (hepatocytes in the liver), unlocked >\$35bn in company value and is the delivery system for 47 assets in the clinic with 6 approvals. Sixfold will find 'GalNAcs' for multiple cell types. M&A: Dicerna \$3.3bn; DtX Pharma \$1bn; Medicines Co. \$9.7bn. Public: Alnylam (\$23bn); Sarepta (\$11bn); Ionis (\$7bn).

TRACTION INDICATORS

Partnership with a top-10 pharmaceutical company. Collaborators: CPI, MHRA, Medicines Discovery Catapult. >35 *in vivo* studies undertaken to-date, with clear improvements over industry benchmarks in multiple organs. 2 UPTO Patents granted. Platform output is hitting exponential growth, generating *in vivo* data orders of magnitude faster than competition.

STAGE INDICATORS

Raised >\$16m in dilutive and non-dilutive funding to de-risk their delivery platform. Highly competitive grant funding from Innovate UK (SMART, BMC), Wellcome Trust and European Commission. Series A capital deployed to scale commercial ambitions (upfront £40m+ deals) and build the world biggest delivery dataset in multiple cell types in next 12 months.

STRENGTH OF TEAM

Globally recognised leadership and technical team from leading institutions: Cambridge, Oxford, MIT, AstraZeneca, Roche, DeepMind, Airbus, etc.

- Dr Tina Flatau, CBO – ex. PwC, Prosensa through IPO (Nasdaq: RNA)
- Dr Anna Perdrix Rosell, co-CEO, founder – CRICK PhD, Forbes 30u30
- Dr George Foot, co-CEO, founder – Cambridge PhD, Forbes 30u30
- Dr Søren Ottosen, VP R&D – ex. Roche, RNA, external innovations lead.

Round

- £16,000,000
- Series A
- Open - co-lead in place.

Current Investors


- Cantos
- Y Combinator
- TVC

Company HQ

- London

Employees

- 29 FTEs



Round

- £20 million
- Series A
- Q4 2024

Current Investors

- IQ Capital
- Northern Gritstone

Company HQ

- Manchester, UK

Employees

- 11

VALUE STATEMENT

Enzyme technology has applications from sustainable and efficient chemical manufacturing to new diagnostic tools and therapeutics. Current approaches to developing enzymes are deemed inefficient and time-consuming. Imperagen is attempting to reinvent enzyme engineering to address the market needs of speed, capacity, and scalability. The company integrates patented advances in AI, precision DNA editing and laboratory automation in a unique platform to accelerate enzyme engineering; they call it Digital Enzyme Evolution™.

MARKET INDICATORS

Chemical manufacturing is a global \$11tn market, which includes fine chemicals and pharmaceuticals, of which the addressable market for enzymes is around \$10bn (CAGR 8%). Enzymes are also employed for life sciences tools, with a market size for engineered enzymes of \$38bn. Within that, the opportunity for engineered enzymes in chiral chemistry is \$2bn. Imperagen estimate within this segment alone the serviceable addressable market is over \$500m.

TRACTION INDICATORS

Two successful Innovate UK grants totalling over £750k. Imperagen is working with a major European enzyme supplier and our customer pipeline is rapidly expanding across chemical and pharmaceutical manufacturing and engineered enzymes for diagnostics and therapeutics. Projecting revenue of £50m by delivering up to 20 new enzymes per year by 2029 (CAGR 150%). Low regulatory hurdles mean rapid time to market allowing breakeven within that timeframe.

STAGE INDICATORS

Spun out of The University of Manchester 2021. £3.5m seed funding round closed in Q3 2022; seed capital has been used to fund technical and commercial validation. On track to hit seed stage milestones. Plans to build a production scale fully automated AI and laboratory automation platform to meet growing demand for engineered enzymes.

STRENGTH OF TEAM

Peter Seuffer-Wasserthal (Chair): Over 30 years of industrial biotechnology and life sciences commercialisation experience.

Andrew Almond (Founder & CEO): serial entrepreneur, co-founded C4X Discovery, led the company through successful fundraising and exit on AIM.

Andrew Currin (Founder & CSO): leading expert in the field of directed evolution, enzymology, and synthetic biology.

Tim Eyes (Founder & CPO): Protein engineer who started his career in a therapeutic antibody technology spin-out, Neutec Pharma that was exited to Novartis. PhD in Biotechnology and held an Enterprise Fellowship at the University of Manchester.

Oxford Drug Design



Round

- £17,000,000
- Series A
- Q2 2024

Current Investors

- O2h Ventures,
- IP Group,
- Angel Co-Fund,
- University of Oxford,
- Jonathan Milner

Company HQ

- Oxford, UK

Employees

- 8

VALUE STATEMENT

ONCOLOGY DRUG DISCOVERY ACCELERATED BY PROPRIETARY AI. OXFORD DRUG DESIGN (ODD) are a pre-clinical therapeutics spinout from Oxford University developing innovative small-molecule treatments against cancer and other major diseases. Their AI drug discovery platform (SynthAI) overcomes inefficiency limitations of current methods and accelerates the potential impact for patients. This differentiated capability has already delivered *in vivo* proof of concept for a first-in-class approach against cancer and plans for further efficient discovery of new drugs are in development.

MARKET INDICATORS

Killing one of every six people worldwide and over 10m deaths per year, cancer remains a top priority for modern medicine to treat and cure. The report “Cancer Therapy Market Size & Share Analysis - Trends & Forecasts 2024-29” indicates a current value of \$220bn and growing at 11% p.a. with the largest current market being North America and the fastest growing Asia-Pacific. Initially the company aims to overcome the weaknesses in efficacy and safety of an existing class of drugs which sold over \$1bn for several of those priority cancers.

TRACTION INDICATORS

ODD has been awarded \$9m in grants from UK, US and EU funding agencies and has validated the platform and discovery pipeline. Each of their two lead programmes has reached successful *in vivo* proof-of-concept, with potential annual sales of \$1bn each. Licensing deals for drugs affecting this pathway have been in the \$300m-\$800m range. Using the AI platform, ODD are rapidly scaling to multiple further high value opportunities.

STAGE INDICATORS

Seed investment followed by bridging round of £2.3m have been used as planned to achieve *in vivo* validation of their first-in-class approach against cancer, meeting all pre-agreed milestones. Series A will fund identification and pre-clinical development of the oncology clinical candidate (scheduled for Q3 2025), strengthen the SynthAI discovery platform and expand the drug pipeline.

STRENGTH OF TEAM

- CEO Dr Alan D Roth (Merck, McKinsey, Commerzbank Asset Management, Chiral Quest)
- CSO Dr Paul W Finn (Pfizer, SmithKline Beecham, TopoTarget)
- Head of Biology Dr Michael Dawson (Glaxo/GSK, Novacta, Cantab)
- Head of Machine Learning Dr Richard Cooper (Oxford Diffraction, InhibOx, University of Oxford)
- Chairman Prof Graham Richards CBE FRS (University of Oxford) Computational chemistry pioneer

Valink Therapeutics



Round

- £25,000,000
- Series A
- Opening mid-2025

Current Investors

- RV Invest
- Hoxton Ventures
- SynBioVen
- Y Combinator
- P53 Invest
- Metaplanet
- Magnet Ventures
- Acequia Capital

Company HQ

- London

Employees

- 13

VALUE STATEMENT

Valink Therapeutics discovers novel bispecific antibody-drug conjugates (ADCs) to address toxicity and resistance challenges in cancer treatment. Current ADCs are limited by a shared landscape of cancer markers, leading to toxicity and resistance. By leveraging dual-target specificity, bispecific ADCs achieve greater on-tumour precision while sparing healthy cells. Utilising Valink's Universal Assembly Platform™, novel target combinations can be discovered at high-throughput to make safe and effective first-in-class bispecific ADCs for various tumour indications.

MARKET INDICATORS

Valink focuses on solid tumours, including colorectal cancer (CRC), the third most common cancer worldwide with 1.9m cases and 0.9m deaths annually. Notably, current treatments only increase patient median survival by 1-2 months. The global CRC market is at £9bn with 4.7% CAGR (£13.3bn by 2030), of which the advanced CRC therapeutics market is £4.7bn with 4.2% CAGR (£6.9bn by 2030). There is significant blockbuster drug potential considering sales of current antibody treatments reaching ~£1bn annually. Additional solid tumour types are in pipeline.

TRACTION INDICATORS

Valink is a spin-out of the University of Oxford, graduated from top startup accelerators (Y Combinator, Creative Destruction Lab), it has filed 3 patents on the company's platform, and won 1 Innovate UK grant. The bispecific ADC discovery platform now exceeds the throughput scale of big pharma, e.g. Merck KGaA, and has shortlisted multiple novel target combinations for lead identification.

STAGE INDICATORS

Valink Therapeutics has raised £7.3m (\$9.2m) across two equity rounds and a UK grant funding. The proceeds are being used to deploy the Universal Assembly Platform™ for two drug discovery programmes. The first lead drug candidate is expected by end 2024. Series A in 2025 will be used to progress the lead drug to IND-enabling studies.

STRENGTH OF TEAM

- **Dr Arne Scheu, Founder CEO:** Oxford protein engineer, Rhodes Scholar
- **Dr Irsyad Khairil, Founder CTO:** Oxford protein biochemist, pharma consultancy
- **Dr Jose Munoz-Olaya, CSO:** Director of Preclinical Takeda, Head of Preclinical Adaptate (acquired by Takeda), AstraZeneca, F-star
- **Dr Alexey Lugovskoy, NED:** Antibody expert, CEO Diagonal Tx, COO Dragonfly Tx, CDO Morphic Tx, VP Merrimack

PharmEnable Therapeutics



VALUE STATEMENT

PharmEnable Tx is a drug discovery company accessing the inaccessible by reimagining small molecules through AI. While monoclonal antibody therapeutics have transformed oncology due to their exquisite selectivity, they are not able to access disease targets inside the cell, where **two thirds** of all human proteins are located. PharmEnable aim to bridge this substantial therapeutic gap by using AI to design small molecules with the specificity of antibodies.

Round

- £24,000,000
- Series A
- Q1 2025

Current Investors

- MP Healthcare (venture arm of Mitsubishi Tanabe)
- Cambridge Enterprise
- Parkwalk
- Heyford Trust
- o2h Ventures
- Martlet Capital
- Arrowfield Capital
- Wren Capital
- R42 Group
- Experienced life sciences angel investors including Jonathan Milner

Company HQ

- Cambridge, UK

Employees

- 17

MARKET INDICATORS

PharmEnable's lead programme focuses on applying their technology to a first-in-class therapy for Myc-driven ovarian cancer, affecting 200,000 patients globally with only a 49% 5-year survival rate. The global ovarian cancer market size reached US\$2.1bn in 2023 and is expected to reach US\$5.1bn by 2032 (10% CAGR).

TRACTION INDICATORS

Partnerships:

- Expanded partnership with Nxera (formerly Sosei Heptares) in 2023 to include a second neurology programme.

Awards:

- Rising Star, DeepTech Investment of the Year 2021 from UKBAA
- Collaboration Deal of the Year 2022 from Pharmaceutical Licensing Group

STAGE INDICATORS

The company has so far raised £8m of equity funding - £2m in a 2020 seed round and £6m in their 2023 pre-series A round. PharmEnable is currently raising a small extension of £2.3m. Their lead programme is at the optimisation stage and they expect to obtain *in vivo* POC data in 2025.

STRENGTH OF TEAM

- **Dr Hannah Sore, CEO and co-founder** – A medicinal chemist by training with 25+ years of experience in life sciences (Millennium Pharmaceuticals, Astex Therapeutics, University of Cambridge). During her time at Astex, she contributed to the discovery stage of Truqap (capivasertib), now FDA approved for the treatment of metastatic breast cancer.
- **Dr Natalia Mateu, CSO and co-founder** – 15+ years of organic and medicinal chemistry research within pharmaceutical and academia (University of Cambridge, Janssen/J&J).

Leadership team:

- **Dr David Vidal, Director of Technology** (Mind The Byte, ChemoTargets)
- **Dr Kyla Grimshaw, Director of Biology** (Sentinel Oncology, Horizon Discovery)
- **Dr James Dale, Director of Chemistry** (Novartis, BenevolentAI)



VALUE STATEMENT

BIOS is using AI to create the data infrastructure for precision medicines which treat diseases of the nervous system and brain. BIOS is building the infrastructure on which future neural treatments will be discovered, developed, and delivered. BIOS has developed neural interfaces and AI that, can read and write the body's neural data or 'code', to understand and correct signals faulty in real-time.

MARKET INDICATORS

The global precision medicine market is projected to reach \$216.75bn by 2028, CAGR of 11.5% from 2021 to 2028. The neurotechnology market has gained significant traction in recent years with Neuralink's first human implant and Blackrock Neurotech's recent \$200m partnership with Tether. BIOS Health's AI-driven platform has diverse applications across various sectors, including healthcare, pharmaceuticals, and research institutions, presenting multiple revenue streams and opportunities for strategic partnerships.

TRACTION INDICATORS

The National Institute of Health funded VESPA trial is a multi-centre trial powered by BIOS technology to evaluate the effects of Vagus Nerve Stimulation on multiple organs. BIOS has confidential contracts with a top ten pharmaceutical company and prominent medical device company, validating the value of its neurotechnology platform. The company has forged strategic partnerships with leading institutions such as the Mayo Clinic, Stanford and Monash universities. BIOS has received prestigious accolades such as: COGX Best Innovation In Personalised Medicine 2021, Wired Health EY Startup Of The Year 2022.

STAGE INDICATORS

Raised £27.4m in funding equally from VC investment and non-dilutive funding. BIOS also has a global research presence, with an AI R&D centre in Montreal and recently established presence in Central California. New funding will bolster the team and expand its product pipeline, focusing on the development of novel digital therapies through their Autonomic Therapy Initiative for the prevention and treatment of heart failure and four similar programs.

STRENGTH OF TEAM

Emil Hewage, Co-Founder & CEO: Forbes 30 under 30, MIT 35 under 35, University of Cambridge

Oliver Armitage, Co-Founder & CSA: PhD University of Cambridge, Selvedge Ventures Technology Fellow

Prof Joanne Hackett, Chair: VP Health Systems Services at IQVIA, Harvard Medical School

Prof Tim Denison, Scientific Advisor: Professor of Engineering Science and Clinical Neurosciences at Oxford University

Round

- £25,000,000+
- Growth Round
- Q2 2024

Current Investors

- Y-Combinator
- XTX Ventures
- Kern Venture Group
- Fifty Years VC
- Selvedge Ventures
- Endure Capital

Company HQ

- Cambridge, UK

Employees

- 45



Round

- £60,000,000
- Series A
- Q3 2024

Current Investors

- Ahren Innovation
- OMX Ventures, Amadeus Capital Partners
- General Inception

Company HQ

- Cambridge

Employees

- 29 FTEs

VALUE STATEMENT

Based on Jason Chin's work at the MRC's LMB, Constructive Bio is revolutionising biotechnology using its proprietary genome writing and genetic reprogramming. The Company's state-of-the-art technologies have yielded virus-resistant organisms capable of producing an entirely new generation of therapeutics and sustainable biomaterials. The core technology uses bacterial strains to synthesise novel biopolymers including non-canonical canonical amino acids, allowing exploration of chemical space not accessible to natural biology and enabling the scalable synthesis of proteins, peptides and other biopolymers.

MARKET INDICATORS

The core technology enables the fundamental reprogramming of the genetic code, and the generation of new-to-nature polymeric molecules including peptides, proteins and polymers

- Peptides (therapeutics, biopesticides, cosmetic products, others)
- Proteins (Including ADCs with precise non-canonical bioconjugation handles)
- Modular assemblies (Including immunocytokines and complex biologics)
- Novel polymers (Bioplastics and other advanced materials)

The Company's strategy is to develop its own commercial products (strains and programmable biomolecules), to co-create value with high-impact players and out-license the platform to unique partners

TRACTION INDICATORS

The company has demonstrated the ability to writing entire genomes from scratch using multiomics-driven in silico design and physical construction of Mbp-scale DNA. Flagship strain Syn61 has built in firewalls against phage attack and horizontal gene transfer and is the first of a new class of synthetic organisms designed for reliable and safe biomanufacturing and allows incorporation of hundreds of different non-canonical amino acids.

STAGE INDICATORS

Proprietary platforms (ownership/exclusive license to 17 patents and applications,) are validated with results in leading publications, now fully available and operational in-house. A £12.4M Seed round closed in May 2022. Now raising £60M Series A to expand Its Pipeline and Enhance Its Platform.

STRENGTH OF TEAM

- **Ola Wlodek PhD (PhD, MBA):** previously COO at Reflection Therapeutics.
- **Prof. Jason Chin PhD FAMS, FRS (CSO and Founder):** MRC LMB. EMBO Gold Medal and the Royal Society's Francis Crick Prize



Department for Business and Trade

The UK's Department for Business and Trade (DBT) has overall responsibility for promoting UK trade across the world and attracting foreign investment to our economy. We are a specialised government department with responsibility for negotiating international trade policy, supporting business, as well as delivering an outward-looking trade diplomacy strategy.

Disclaimer

Whereas every effort has been made to ensure that the information in this document is accurate, the Department for Business and Trade and the Contributors does not accept liability for any errors, omissions or misleading statements, and no warranty is given or responsibility accepted as to the standing of any individual, firm, company or other organisation mentioned.

© Crown copyright 2022

This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3

Where we have identified any third-party copyright information you will need to obtain permission from the copyright holders concerned.

Published by Department for Business and Trade: April 2022